Kaisa Huhtinen
PhD, Adjunct Professor in Cancer Biology
kaisa.huhtinen@utu.fi +358 29 450 2645 +358 50 572 6733 Kiinamyllynkatu 10 Turku Office: D5038 ORCID identifier: https://orcid.org/0000-0001-9685-5246 |
Areas of expertise
Ovarian cancer; personalized medicine; early diagnostics; prediction; prognosis; biomarker; genomics; drug target; interdicipline research;
Ovarian cancer; personalized medicine; early diagnostics; prediction; prognosis; biomarker; genomics; drug target; interdicipline research;
Biography
Research
Publications 
1 of 4
- MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer (2025)
- Scientific Reports
(A1 Refereed original research article in a scientific journal) - Deciphering cancer genomes with GenomeSpy : a grammar-based visualization toolkit (2024)
- GigaScience
(A1 Refereed original research article in a scientific journal) - Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma (2024)
- BMC Cancer
(A1 Refereed original research article in a scientific journal) - HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma (2024)
- Gynecologic Oncology
(A1 Refereed original research article in a scientific journal) - Locus-specific LINE-1 expression in clinical ovarian cancer specimens at the single-cell level (2024)
- Scientific Reports
(A1 Refereed original research article in a scientific journal) - PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures (2024)
- Neoplasia
(A1 Refereed original research article in a scientific journal) - Aberrant glycosylation of α3 integrins as diagnostic markers in epithelial ovarian cancer (2023)
- Clinica Chimica Acta
(A1 Refereed original research article in a scientific journal) - A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids (2023)
- Developmental Cell
(A1 Refereed original research article in a scientific journal) - Circulating tumor DNA-based copy-number profiles enable monitoring treatment effects during therapy in high-grade serous carcinoma (2023)
- Biomedicine and Pharmacotherapy
(A1 Refereed original research article in a scientific journal) - Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma (2023)
- Cancer Cell
(A1 Refereed original research article in a scientific journal) - Quantification of cell death and proliferation of patient-derived ovarian cancer organoids through 3D imaging and image analysis (2023)
- STAR protocols
(A1 Refereed original research article in a scientific journal) - Toxicity and therapy outcome associations in LIG3, SLCO1B3, ABCB1, OPRM1 and GSTP1 in high-grade serous ovarian cancer (2023)
- Basic and Clinical Pharmacology and Toxicology
(A1 Refereed original research article in a scientific journal) - Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer (2022)
- International Journal of Cancer
(A1 Refereed original research article in a scientific journal) - Dubious effects of methadone as an “anticancer” drug on ovarian cancer cell-lines and patient-derived tumor-spheroids (2022)
- Gynecologic Oncology
(A1 Refereed original research article in a scientific journal) - Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status (2022)
- Frontiers in Oncology
(A1 Refereed original research article in a scientific journal) - Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancerQuantISH: RNA in situ hybridization image analysis framework for quantifying cell type-specific target RNA expression and variability (2022)
- Science AdvancesLaboratory Investigation
(A1 Refereed original research article in a scientific journal) - Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246-Sensitive Disease Subtype (2022)
- Molecular Cancer Therapeutics
(A1 Refereed original research article in a scientific journal) - (2022)
(A1 Refereed original research article in a scientific journal) - Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality (2021)
- Scientific Reports
(A1 Refereed original research article in a scientific journal) - A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer (2021)
- Cancers
(A1 Refereed original research article in a scientific journal)
UTU Research Portal